AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03530254 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PGT-A
Description: PGT-A will be carried out following the usual clinical practice. Trophectoderm biopsy samples from blastocysts are analyzed by NGS to screen for numerical chromosomal abnormalities.
Study NCT03530254 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ERA Test
Description: The ERA test requires an endometrial biopsy and will determine if the endometrium is receptive or not by analysing the expression levels of 236 genes involved in endometrial receptivity, to assess the optimal time to place an embryo into the uterus and promote a successful implantation and pregnancy.
Study NCT03982108 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair with knotless suture-bridge technique
Description: A posterior portal will be established to obtain adequate visualization and an anterior portal will be established through rotator interval as a working portal for diagnostic arthroscopy and debridement. Then additional portals will be established and preperation of tendon will be performed and a burr will be used for footprint preperation.~After determination of proper anchor locations, required number of suture anchors will be inserted just lateral to articular margin depending on the tear size. Then limbs of sutures will be passed from the rotator cuff and will be used to create a suture bridge over the tendon. Then these limbs will be loaded to anchors which will form the lateral row without tying the suture limbs at the medial row. These lateral anchors will be inserted to adequate location, just lateral and distal to greater tuberosity with adequate suture-bridge tension over the rotator cuff.
Study NCT03982108 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic rotator cuff repair with knot-tying suture-bridge technique
Description: After the same preparation procedure as in knotless suture-bridge technique, required number of suture anchors will be inserted just lateral to articular margin depending on the tear size. Then limbs of sutures will be passed from the tendon and tied in a horizontal mattress suture pattern. After the establishment of medial row, suture limbs will be used to form a suture bridge over the tendon and will be loaded to lateral row anchors which then will be inserted lateral to greater tuberosity in a similar way to knotless repair technique.
Study NCT04136093 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the MED
Description: The MED diet will be composed of the basis food items traditional for the Mediterranean region i.e. olive oil, nuts, vegetables, fruits, and fish and this diet will be given an ad libitum approach. The MED diet will be giving a higher proportion of fat, at least 40% of the total energy, with 20% of the total energy from MUFAs, and less proportion of carbohydrates. To ensure the assumed supply of MUFAs and polyunsaturated fatty acids (PUFAs), the participants will be asked to daily intake 60 g (6 spoons) of extra virgin olive oil and 30 g (6 pieces) walnuts.
Study NCT04136093 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the DASH
Description: The DASH diet will be giving a higher proportion of carbohydrates, at least 60% of total energy and less fat. The DASH diet will be composed wholegrain cereal products, fruit, vegetables, low-fat dairy products, fish, seafood, poultry, beans, seeds and nuts and will be recommending eating of the traditional polish food items for example oatmeal, rye bread, barley groats, apples, plums, etc. and reducing the supply of salt, sweets, sugars, fats especially saturated fats and red meat. In our study, the DASH diet will be given an ad libitum approach. The sufficient supply of carbohydrates and β glucans in the DASH diet will be ensured by daily consumption at least 50g oatmeal and 50g of barley groats.
Study NCT04136093 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control diet
Description: The control group will only receive oral dietary recommendations based on the Harvard model Healthy Eating Plate, that recommend to eat a half of plate of vegetables and fruit, a quarter of plate of whole grains products, and a quarter of plate of protein products for one meal.
Study NCT01262560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Manuka honey in liquid form
Description: Patients swallow 10 cc (approximately 2 level teaspoons) of liquid Manuka honey 4 times per day while awake over an approximately 12 hour period (e.g. 8 a.m., Noon, 4 p.m., and 8 p.m.) 7 days/week during concurrent chemotherapy and radiation treatment.
Study NCT01262560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Manuka honey in lozenge form
Description: Patients place 2 lozenges (the equivalent of 10 cc of liquid Manuka honey), one at a time, in the mouth, allowing each lozenge to dissolve on the tongue/in the mouth, swallowing the honey as it dissolves. Patients do this 4 times per day while awake over an approximately 12 hour period (e.g. 8 a.m., Noon, 4 p.m., and 8 p.m.) 7 days/week during concurrent chemotherapy and radiation treatment.
Study NCT01262560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard supportive care
Description: Patients receive standard supporting care for esophagitis-related pain as needed during concurrent chemotherapy and radiation treatment. The following regimen is recommended, but the local standard of care is permitted.~1. A compound containing viscous lidocaine and magnesium aluminum oxide (Maalox®);~2. Liquid or solid oxycodone, 5-10 mg, every 3 hours as needed.
Study NCT03026231 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRIM-DJ2727
Description: Thirty eligible subjects with PD will be randomly assigned to receive either PRIM-DJ2727 in orally administered enteric-coated capsules or placebo capsules
Study NCT03026231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for PRIM-DJ2727)
Description: Thirty eligible subjects with PD will be randomly assigned to receive placebo capsules
Study NCT04772625 — intervention group
Intervention type: DEVICE
Intervention: Patellofemoral arthroplasty
Description: Insertion of an artificial joint between the front of the femur and the back of the patella. The femoral component consists of a metal implant, and the patellar component is a polyethylene implant. The two components replace the original articular cartilage of the patellofemoral joint.
Study NCT02543073 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSCs
Description: MSCs will be given at a median dose of 1×10\^6 cells/kg once weekly for 4 weeks as one cycle treatment.
Study NCT02543073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZM
Description: AZM will be given （0.25g qd）for 4 weeks as one cycle treatment.
Study NCT02543073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZM
Description: AZM will be given （0.25g qd）for 4 weeks as one cycle treatment.
Study NCT02543073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoid
Description: Glucocorticoid (prednison) will be given at the starting dose of 1mg/kg for 4 weeks as one cycle treatment.
Study NCT02543073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoid
Description: Glucocorticoid (prednison) will be given at the starting dose of 1mg/kg for 4 weeks as one cycle treatment.
Study NCT02905539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Isomaltoside 1000
Study NCT02905539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Carboxymaltose
Study NCT03292640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD-03 (0.1% tazarotene) Lotion
Description: DFD-03 Lotion (0.1% tazarotene) - twice daily application
Study NCT03292640 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DFD-03 (0% tazarotene) Lotion (Placebo)
Description: DFD-03 Vehicle Lotion (0% tazarotene) - twice daily application
Study NCT02122666 — intervention group
Intervention type: PROCEDURE
Intervention: muscle biopsy
Description: A member of the study team will obtain a small sample of muscle tissue from the patient's thigh (vastus lateralis muscle).
Study NCT03781973 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Data platform +Quality Performance feedback reports
Description: Teams from each of the participating sites will attend the webinars. Each site will share an example of a QI initiative that they are executing and describe the success and challenges.
Study NCT03685903 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CapsoCam® Plus (SV-3) capsule endoscope
Description: Endoscope Capsule
Study NCT02337101 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: All patients will have a brief clinical psychiatric and neurological assessment in order to determine eligibility, and will be provided with information and advice about typical post-concussional symptoms, the typical recovery process and the use of pain medication.
Study NCT02337101 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EUC + Early intervention programme
Description: All patients will have a brief clinical psychiatric and neurological assessment in order to determine eligibility, and will be provided with information and advice about typical post-concussional symptoms, the typical recovery process and the use of pain medication.~The early intervention programme will be interdisciplinary and will mainly be provided by an occupational therapist and a physiotherapist under supervision of a neuropsychologist. It will be based on psychoeducation and principles from Cognitive Behavioral Therapy and Graded Exercise Therapy and targeted to patients' individual goals.~Patients will receive 8 weekly treatment sessions (3 group based and 5 individual sessions). Intervention will start approximately 4-5 months after the concussion.
Study NCT04055272 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile text messaging intervention
Description: Participants in the intervention arm will receive text messages to their mobile phones designed to communicate the risks of indoor tanning and motivate cessation. The intervention exposure lasts for 4 weeks with messages sent 2 days each week. It is an interactive intervention that engages participants by asking them to respond to prompts, and sending indoor tanning message content in return on message days.
Study NCT01788397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Swimming, physiotherapy, water therapy, alpine skiing, xc-skiing, hippotherapy, climbing, cycling, rowing
Study NCT02620800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU
Description: 5 fluorouracil (5-FU) (180 mg/m\^2/day for 14 days) by CIVI via ambulatory pump
Study NCT02620800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel (75 mg/m\^2) as a 30-minute (min) IV infusion on Days 1, 8, and 15
Study NCT02620800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: bevacizumab (5 mg/kg) as an IV infusion on Days 1 and 15
Study NCT02620800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium leucovorin
Description: calcium leucovorin (20 mg/m\^2) IV bolus, on Days 1, 8, 15
Study NCT02620800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: oxaliplatin (40 mg/m\^2) as a 60-min IV infusion on Days 1, 8, and 15
Study NCT04475419 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preformed stainless steel crowns cemented by glass ionomer luting cement(Ketac Cem, 3M Espe)
Description: covering the affected molar with preformed metal crown cemented by glass ionomer luting cement(Ketac Cem, 3M Espe)
Study NCT01774669 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YouGrabber training device from YouRehab Ltd.
Description: Patients in the experimental group (EG) will receive 16 training sessions lasting for 45 minutes each. The treatment focus is the upper extremity, in particular finder and hand function, movement coordination, and speed.
Study NCT01774669 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapy (PT, OT)
Description: Patients in the control group (CG) will receive 16 therapy sessions physiotherapy or occupational therapy) lasting for 45 minutes each. The therapy focuses on upper limb movements, in particular finger and hand movements. Furthermore, movement coordination and speed shall be trained.
Study NCT03545087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanabecestat
Description: Administered orally
Study NCT03545087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: Administered intravenously. Administration is at investigator's discretion in participants with severe renal impairment.
Study NCT03435120 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT03312790 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Tasks
Description: Augmented reality device Real condition
Study NCT03312790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tasks
Description: Augmented reality device Real condition
Study NCT02945358 — intervention group
Intervention type: PROCEDURE
Intervention: adult cardiac surgery with cardiopulmonary pump
Description: Open-heart surgery both coronary artery bypass graft (CABG) and valve surgery
Study NCT02016716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab 90 mg/mL
Description: Administered as 2 SC injections of a 90 mg/mL concentration in a 1.17 mL crystal zenith resin prefilled syringe (PFS).
Study NCT02016716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 90 mg/mL
Description: Placebo administered as 2 SC injections with the 1.17 mL crystal zenith resin PFS.
Study NCT02016716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab 70 mg/mL
Description: Administered as 3 SC injections of a 70 mg/mL concentration in a 1.0 mL glass PFS.
Study NCT02016716 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 70 mg/mL
Description: Placebo administered as 3 SC injections with the 1.0 mL glass PFS.
Study NCT02248649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured physical activity
Description: Walking instruction and encouragement
Study NCT02248649 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Provision of general information about a variety of health topics
Study NCT04734483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: spirometry
Description: spirometry
Study NCT04734483 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: MRI and CT
Description: MRI and CT
Study NCT04734483 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laryngoscopy
Description: laryngoscopy
Study NCT04734483 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: electromyography
Description: electromyography
Study NCT01505036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMARTCARE service
Description: U-Healthcare service
Study NCT05026840 — intervention group
Intervention type: PROCEDURE
Intervention: GDM screening criteria
Description: difference in risk factors and clinical outcomes between groups
Study NCT01832389 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PiCCO
Study NCT02504398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fast injection speed by immunizer
Study NCT02504398 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Slow injection speed by immunizer
Study NCT03954834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study NCT03954834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT01188278 — intervention group
Intervention type: DRUG
Intervention: Imatinib
Description: Drug being observed but not provided
Study NCT01631071 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Virosomal influenza vaccine
Description: Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL virosomal influenza vaccine
Study NCT02601638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Demographics and Health History Questionnaire
Study NCT02601638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-Class Laryngectomy Survey
Study NCT03529825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin will be administered twice a day orally or by nasogastric tube, at a dose of 15 mg/kg divided BID with a maximum dose of 1,650 mg, day -7 to day +28 or discharge (maximum duration 36 days).
Study NCT04322110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PronoKal Method
Description: Multidisciplinary program of weight loss based on diet (initially ketogenic diet), physical activity and emotional support
Study NCT04322110 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low calorie diet
Description: Balanced hypocaloric diet (caloric intake 10% below basal metabolic rate) accompanied by physical exercise.
Study NCT02076490 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical/Occupational therapy
Description: At least 10 individual sessions over the clinical intervention period of 4 weeks followed by a 6 weeks self-management phase.
Study NCT02076490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical/Occupational therapy
Description: At least 10 individual sessions over the clinical intervention period of 4 weeks followed by a 6 weeks self-management phase.
Study NCT03398070 — intervention group
Intervention type: OTHER
Intervention: Standard of Care
Description: The standard of care interventions for Functional Neurological Disorders (FND) include:~1. delivery of a rule-in diagnosis~2. providing educational materials~3. referring to physical therapy (PT) and/or occupational therapy (OT) as clinically indicated~4. referring to FND-related cognitive behavioral therapy (CBT)~5. psychotropic medication management based on standard psychiatric care
Study NCT03893565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2831781 - Double Blind Phase
Description: GSK2831781 will be administered intravenously in the double blind induction phase and subcutaneously in the double blind ETP (both according to randomization).
Study NCT03893565 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (commercial saline solution) will be administered intravenously in the double blind induction phase and subcutaneously in the double blind ETP (both according to randomization).
Study NCT03893565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2831781 - Open Label phase
Description: GSK2831781 will be administered intravenously in the open label induction phase and subcutaneously in the open label ETP.
Study NCT04918485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preoperative psychological intervention
Description: including closing the relationship between nurse and patient , knowledge education,
Study NCT00813800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline (Chantix®, Pfizer) is an oral medication with a recommended dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4-7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment.
Study NCT04256512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02840929 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Second-look OGD
Description: Second-look OGD within 16 to 24 hours after primary OGD
Study NCT02840929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Study NCT02840929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Study NCT03566992 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric
Description: Placement of a nasoenteric tube
Study NCT03566992 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric
Description: Placement of a nasoenteric tube
Study NCT02835235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC9204-0530
Description: Administered daily subcutaneously (s.c., under the skin)
Study NCT02835235 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered daily subcutaneously (s.c., under the skin)
Study NCT00471315 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Duloxetine
Description: A preliminary, open-label single center study of duloxetine in patients with SOD
Study NCT01250899 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 50,000 IU vitamin D3 twice weekly for 5 weeks, followed by 2000 IU daily maintenance supplementation to complete 12 weeks. At the end of the 12-week period, 25(OH)D levels will be checked. If the subject is still deficient, he/she may undergo a second period of supplementation (at the discretion of their provider) to complete a total of 24 weeks. After 24 weeks, we anticipate all subjects will be kept on daily maintenance supplementation by their primary physicians.
Study NCT02620124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natural cycle: Triptorelin acetate 0.1 mg
Description: A single dose of triptorelin acetate 0.1 s.c. was giwen when the age of the transferred embryo was six days in additon to standard micronized progesterone 400 mg vaginally
Study NCT02620124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormone replacement cycle and triptorelin acetate 0.1 mg
Description: A single dose of triptorelin acetate 0.1 s.c. was giwen when the age of the transferred embryo was six days in addition to standard Estradiol and progesterone support